EGFR

[Cancer Discovery] The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.

[British Journal of Cancer] Scientists highlight regulatory mechanisms and signaling pathways that cause therapy-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

[Nature Communications] Scientists investigated the oncogene-specific dependencies conferred by the lung cancer oncogene, RIT1. Genome-wide CRISPR screening in KRAS, EGFR, and RIT1-mutant isogenic lung cancer cells identifies shared and unique vulnerabilities of each oncogene..

[Cancer Letters] Investigators reported that the upregulated C-MET signaling acted as a compensatory mechanism that sustained the proliferation of chemoresistant cells in which EGFR family signaling was attenuated.

[JCI Insight] In mammary epithelial cells of transgenic mouse models, and breast cancer cell lines, HER2 hyperactivation altered GPCR expression, particularly, Gi/o-GPCRs.

[Oncogene] Researchers reported that the expression of CRYβB2 in breast cancer cells increased stemness, growth, and metastasis. Transcriptomics data revealed that CRYβB2 upregulated genes that were functionally associated with unfolded protein response, oxidative phosphorylation, and DNA repair, while down-regulating genes related to apoptosis.